Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Inhaled Nitric Oxide in Intubated COVID-19 Patients
NCT04383002Phase 1Completed
- Sponsor
- University Health Network
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of Care with Inhaled Nitric Oxide (2 arms). Primary endpoint: COVID-19 PCR status at completion of treatment at 7 days. Started Sep 2020; status: completed.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04383002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383002.